Home Featured Page 45

Featured

Latest

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

The VA, Psychedelics, and the Future of Mental Health: A Conversation...

Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability...

Harry Pack – Psychedelic Surealism

Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape...

BREAKING: New Mexico Passes Nation’s First Legislature-Driven Psilocybin Access Act

Jean-Francois Sobiecki – African Psychoactive Plants & Phytoalchemy

March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S....

Vince Kadlubek – Meow Wolf & PORTAL

The Tide Is Turning: Psychedelic Therapies Take a Step Toward the...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

LP Giobi – Livestream

The VA, Psychedelics, and the Future of Mental Health: A Conversation...

Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability...

Harry Pack – Psychedelic Surealism

Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape...

BREAKING: New Mexico Passes Nation’s First Legislature-Driven Psilocybin Access Act

Jean-Francois Sobiecki – African Psychoactive Plants & Phytoalchemy

March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S....

Vince Kadlubek – Meow Wolf & PORTAL

The Tide Is Turning: Psychedelic Therapies Take a Step Toward the...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY